A MULTI-CENTRE, OPEN-LABEL PHASE 2 TRIAL OF THE COMBINATION OF VB10.16 AND ATEZOLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT, NON-RESECTABLE HPV16 POSITIVE CERVICAL CANCER